Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Oncology Drugs. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Advanced synthesis of indazole-triazole compounds via click chemistry for Bcr-Abl inhibition. Reliable pharma intermediate supplier offering cost-effective scale-up.
Novel patent CN102557977B details efficient Erlotinib intermediate synthesis offering cost reduction and supply chain reliability for API manufacturing partners.
Patent CN102924548A details a safer Capecitabine synthesis using Lewis acids instead of toxic tin, offering cost reduction and scalable manufacturing for pharmaceutical intermediates.
Patent CN117025699A reveals a chemo-enzymatic route for Larotinib intermediates. Achieve high ee values and reduced costs with scalable pharmaceutical manufacturing solutions.
Patent CN102548987A details novel fluoro-substituted compounds for Bcr-Abl inhibition. Discover scalable synthesis routes and cost-effective manufacturing strategies for high-purity pharmaceutical intermediates.
Patent CN113637002B reveals a green photocatalytic route for Nilaparib intermediates, offering significant cost reduction in API manufacturing and enhanced supply chain reliability.
Patent CN114075143A reveals a one-pot synthesis for Olaparib intermediates, eliminating unstable phosphorus ylide isolation to ensure high purity and cost-effective manufacturing.
Patent CN113024454A reveals a novel synthesis for brigatinib intermediates, offering cost reduction in API manufacturing and enhanced supply chain reliability.
Patent CN108239091B details a robust chemical resolution for NLG919 precursors. This method offers high optical purity, recoverable reagents, and scalable manufacturing for pharmaceutical supply chains.
Patent CN111471020B reveals a novel Rh-catalyzed route for Avapritinib intermediates, offering safer conditions and reduced costs for reliable API manufacturing.
Novel indazole-triazole derivatives with specific anti-prostate cancer activity. Efficient synthesis route offers cost reduction and scalable supply for pharmaceutical intermediates.
Patent CN111057729A details a green enzymatic route for Larotretinib intermediates, offering high ee values and cost reduction in API manufacturing.
Patent CN110950914A reveals a highly selective iridium complex synthesis. Discover cost-effective manufacturing routes for potent cervical and ovarian cancer therapeutics.
Patent CN111875591B details a green one-pot synthesis for benzopyrone intermediates using recyclable ionic liquids, offering significant cost and purity advantages for pharmaceutical manufacturing.
Patent CN106831793B reveals high-yield Beckmann rearrangement for ovarian cancer drug intermediate ensuring cost reduction and supply chain reliability for global pharmaceutical manufacturing.
Patent CN112457293B reveals a high-yield TBTU/DBU method for Lorlatinib, offering significant cost and purity advantages for pharmaceutical manufacturing.
Patent CN107200708B reveals a novel 3-step synthesis for Vismodegib using 2-chloro-5-nitroacetophenone, offering cost reduction and high purity for pharmaceutical manufacturing.
Patent CN114230471A details a robust route for 3,4-dichloro-2-fluoroaniline, offering high purity and cost efficiency for Tesevatinib manufacturing supply chains.
Patent CN103897028A details a heavy-metal-free synthesis of Bortezomib, offering high purity and cost reduction for pharmaceutical manufacturing supply chains.
Patent CN114096529A details a scalable route for Asciminib intermediates using improved Suzuki coupling and amide formation, offering significant cost and purity advantages for pharmaceutical manufacturing.